Micropapillary carcinoma of the bladder (MPBC) is a variant type of infiltrating urothelial carcinoma, which portends a poor biological behavior in terms of disease stage at first diagnosis and clinical outcome; its peculiar morphology raises issues concerning the ability of tumor detection by imaging techniques and proper biopsy procedure, and the appropriate treatment for non-muscle infiltrating and muscle-infiltrating MPBC remains a matter of debate. On the basis of its established prognostic and therapeutic role in breast and gastro-esophageal cancer in the first instance, the human epidermal growth factor receptor-2 (HER2) has been investigated in selected case series of MPBC over the last 10 years. The aim of the present review was to summarize the existing evidence on HER2 status in MPBC, and to discuss its present and future utility in risk assessment and treatment choice of this uncommon, yet aggressive, disease.
CITATION STYLE
Sanguedolce, F., Russo, D., Mancini, V., Selvaggio, O., Calo, B., Carrieri, G., & Cormio, L. (2019). Prognostic and therapeutic role of HER2 expression in micropapillary carcinoma of the bladder (Review). Molecular and Clinical Oncology, 10(2), 205–213. https://doi.org/10.3892/mco.2018.1786
Mendeley helps you to discover research relevant for your work.